10554-64-0

Usage

Uses

Used in Scientific Research:
6-APDB is used as a research chemical for investigating its potential therapeutic properties and understanding its mechanism of action as a selective serotonin releasing agent (SSRA). This research aims to explore its effects on mood enhancement, empathy, and serotonin levels in the brain.
Used in Psychopharmacology Studies:
In the field of psychopharmacology, 6-APDB is utilized to study its psychedelic and stimulant effects, as well as its potential applications in the treatment of various mental health disorders. The hallucinogenic properties of 6-APDB make it a subject of interest for researchers seeking to understand the underlying neurochemical processes associated with these effects.
Used in Controlled Substance Regulation:
Due to its limited research, potential health risks, and popularity in the underground recreational drug scene, 6-APDB is considered a controlled substance in many countries. Its use is regulated to prevent misuse and ensure that any potential therapeutic applications are thoroughly investigated and approved for medical use.

InChI:InChI=1/C10H13NO2/c11-4-3-8-1-2-9-10(7-8)13-6-5-12-9/h1-2,7H,3-6,11H2

Upstream product

• 858789-85-2 3-(2,3-dihydro-benzo[1,4]dioxin-6-yl)-propionic acid amide 
• 17253-10-0 2-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)acetonitrile 
• 14939-92-5 3-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)propanoic acid 
• 29668-44-8 2,3-dihydro-benzo[1,4]dioxin-6-carbaldehyde 
• 10554-65-1 (E)-6-(2-nitrovinyl)-2,3-dihydro[1,4]benzodioxine 
• 139-85-5 3,4-dihydroxybenzaldehyde 

Downstream Products

• 858816-92-9 phenyl-acetic acid-[2-(2,3-dihydro-benzo[1,4]dioxin-6-yl)-ethylamide] 
• 1007755-21-6 N-[2-(2,3-dihydro-benzo[1,4]dioxin-6-yl)-ethyl]-cyclohexanecarboxamide 
• 1233354-50-1 C₂₆H₂₇NO₈S 
• 1233354-63-6 C₂₆H₂₆FNO₈S 
• 1233354-89-6 C₂₅H₂₆FNO₆S 
• 380636-86-2 6-(3,4,5-trimethoxyphenyl)-2,3-dihyhydro[1,4]dioxino[2,3-g]isoquinoline 
• 380636-90-8 6-(3,4,5-trimethoxyphenyl)-2,3,6,7,8,9-hexahydro-[1,4]dioxino[2,3-g]isoquinoline 

Relevant academic research and scientific papers

COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING NASH, NAFLD, AND OBESITY

The present technology relates to methods of treating NASH, NAFLD and/or obesity using compounds of Formulas I, II, III, IV, V, and/or VI. The methods include administering to a subject suffering from one or more of non-alcoholic steatohepatitis (NASH), non- alcoholic fatty liver disease (NAFLD) and/or obesity a therapeutically effective amount of such a compound

Substituted tetrahydroisoquinolines: synthesis, characterization, antitumor activity and other biological properties

This work deals with the molecular design, synthesis and biological activity of a series of tetrahydro[1,4]dioxanisoquinolines and dimethoxyisoquinoline analogues. This study describes the synthesis strategy of these potential antitumor compounds, their multi-step synthesis and their optimization. A series of tetrahydroisoquinolines was synthesized and their cytotoxicity evaluated. Some of these tetrahydroisoquinolines showed promising KRas inhibition, antiangiogenesis activity and antiosteoporosis properties. Molecular modeling studies showed that compound 12 bind in the p1 pocket of the KRas protein making interactions with the hydrophobic residues Leu56, Tyr64, Tyr71 and Thr74 and hydrogen bonds with residues Glu37 and Asp38.

PYRIMIDINE DERIVATIVES AS PGE2 RECEPTOR MODULATORS

The present invention relates to pyrimidine derivatives of formula (I) wherein (R1)n, R3, R4a, R4b, R5a, R5b and Ar1 are as described in the description and their use in the treatment of cancer by modulating an immune response comprising a reactivation of the immune system in the tumor. The invention further relates to novel benzofurane and benzothiophene derivatives of formula (II) and their use as pharmaceuticals, to their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of formula (I), and especially to their use as modulators of the prostaglandin 2 receptors EP2 and/or EP4.

Asymmetric total synthesis and identification of tetrahydroprotoberberine derivatives as new antipsychotic agents possessing a dopamine D1, D2 and serotonin 5-HT1A multi-action profile

An effective and rapid method for the microwave-assisted preparation of the key intermediate for the total synthesis of tetrahydroprotoberberines (THPBs) including l-stepholidine (l-SPD) was developed. Thirty-one THPB derivatives with diverse substituents on A and D ring were synthesized, and their binding affinity to dopamine D1, D2 and serotonin 5-HT 1A and 5-HT2A receptors were determined. Compounds 18k and 18m were identified as partial agonists at the D1 receptor with Ki values of 50 and 6.3 nM, while both compounds act as D2 receptor antagonists (Ki = 305 and 145 nM, respectively) and 5-HT1A receptor full agonists (Ki = 149 and 908 nM, respectively). These two THPBs compounds exerted antipsychotic actions in animal models. Further electrophysiological studies employing single-unit recording in intact animals demonstrated that 18k-excited dopaminergic (DA) neurons are associated with its 5-HT1A receptor agonistic activity. These results suggest that these two compounds targeted to multiple neurotransmitter receptors may present novel lead drugs with new pharmacological profiles for the treatment of schizophrenia.

Compounds and Compositions for Modulating Lipid Levels and Methods of Preparing Same

The present technology relates to compounds of Formulas I-VI and methods of making and using such compounds. Methods of use include prevention and treatment of hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, hepatic steatosis, and metabolic syndrome. Compounds disclosed herein also increase HDL-C, lower total cholesterol, LDL-cholesterol, and triglycerides and increase hepatic LDL receptor expression, inhibit PCSK9 expression, and activate AMP-activated protein kinase.

CORYDALINE DERIVATIVES USEFUL FOR REDUCING LIPID LEVELS

The present technology relates to compounds of Formulas (V) and (VI) and methods of making and using such compounds. Methods of use include prevention and treatment of hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, hepatic steatosis, and metabolic syndrome. Compounds disclosed herein also lower total cholesterol, LDL- cholesterol, and triglycerides and increase hepatic LDL receptor expression, inhibit PCSK9 expression, and activate AMP-activated potein kinase.

Synthesis of isoquinolines and tetrahydroisoquinolines as potential antitumour agents

The isoquinoline 17 and the tetrahydroisoquinoline 16 were synthesized from 2,3-dihydro-1,4-benzodioxin (1) by different synthetic strategies. Preparation of arylethylamines and their cyclization in Bischler-Napieralski conditions have been studied. Another approach to isoquinolines was based on the amination of the ketone 13 followed by cyclization in acidic media. The route via the amide 15 was found to be more successful with respect to both yield and ease of reaction.

Process for the preparation of (8As,12AS,13AS)-decahydroisoquino ((2,1-G) (1,6)-naphthyridin-8-one derivatives

The invention provides a process for preparing single enantiomers of compounds represented by the formula: STR1 and chiral acid addition salts thereof; wherein: X and Y are independently hydrogen; lower alkyl; lower alkoxy; or halo; or X and Y taken together is methylenedioxy or ethylene-1,2-dioxy; which includes reduction of a compound represented by the formula: STR2 to give a mixture of stereoisomers represented by the formula: STR3 wherein each wavy line independently represents a bond in either the α or β position; followed by dissolving the mixture of stereoisomers and a chiral resolving acid in a suitable solvent and allowing the solution to crystallize, giving a salt of the desired enantiomer.